Identification of macrophage migration inhibitory factor and human neutrophil peptides 1-3 as potential biomarkers for gastric cancer

British Journal of Cancer

Volumn 101, Issue 2, 2009, Pages 295-302

  Mohri, Y ^a,b   Mohri, T ^a,c   Wei, W ^a   Qi, Y J ^a   Martin, A ^a   Miki, C ^b   Kusunoki, M ^b   Ward, D G ^a   Johnson, P J ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b MIE UNIVERSITY   (Japan)

^c Toyama Hospital   (Japan)

Author keywords

Biomarker; Gastric; Proteome; Serum

Indexed keywords

BIOLOGICAL MARKER; DEFENSIN 1; DEFENSIN 2; DEFENSIN 3; HUMAN NEUTROPHIL PEPTIDE; MACROPHAGE MIGRATION INHIBITION FACTOR; TUMOR MARKER; UNCLASSIFIED DRUG; ALPHA DEFENSIN; PLASMA PROTEIN; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; ROC CURVE; STOMACH CANCER; STOMACH DISEASE; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; BIOSYNTHESIS; BLOOD; CANCER STAGING; ENZYME LINKED IMMUNOSORBENT ASSAY; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROTEIN MICROARRAY; STOMACH TUMOR;

AGED; AGED, 80 AND OVER; ALPHA-DEFENSINS; BLOOD PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PROTEIN ARRAY ANALYSIS; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 67650588780     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605138     Document Type: Article

References (38)

1. Akbar S, Abe M, Murakami H, Tanimoto K, Kumagi T, Yamashita Y, Michitaka K, Horiike N, Onji M (2001) Macrophage migration inhibitory factor in hepatocellular carcinoma and liver cirrhosis; relevance to pathogenesis. Cancer Lett 171: 125-132
2. Alberts S, Cervantes A, van de Velde C (2003) Gastric cancer: epidemiology, pathology and treatment. Ann Oncol 14: 31-36
3. Albrethsen J, Bogebo R, Gammeltoft S, Olsen J, Winther B, Raskov H (2005) Upregulated expression of human neutrophil peptides 1, 2 and 3 (HNP 1-3) in colon cancer serum and tumours: a biomarker study. BMC Cancer 19: 8
4. Bodger K, Wyatt J, Heatley R (2001) Variation in serum pepsinogens with severity and topography of Helicobacter pylori-associated chronic gastritis in dyspeptic patients referred for endoscopy. Helicobacter 6: 216-224
5. Brozkova K, Budinska E, Bouchal P, Hernychova L, Knoflickova D, Valik D, Vyzula R, Vojtesek B, Nenutil R (2008) Surface-enhanced laser desorption/ionization time-of-flight proteomic profiling of breast carcinomas identifies clinicopathologically relevant groups of patients similar to previously defined clusters from cDNA expression. Breast Cancer Res 10: R48
6. Camlica H, Duranyildiz D, Oguz H, Oral E, Yasasever V (2008) The diagnostic value of macrophage migration inhibitory factor (MIF) in gastric cancer. Pathol Oncol Res 14: 79-83
7. Cunliffe R, Kamal M, Rose F, James P, Mahida Y (2002) Expression of antimicrobial neutrophil defensins in epithelial cells of active inflammatory bowel disease mucosa. J Clin Pathol 55: 298-304
8. de Jong Y, Abadia-Molina A, Satoskar A, Clarke K, Rietdijk S, Faubion W, Mizoguchi E, Metz C, Alsahli M, ten Hove T, Keates A, Lubetsky J, Farrell R, Michetti P, van Deventer S, Lolis E, David J, Bhan A, Terhorst C (2001) Development of chronic colitis is dependent on the cytokine MIF. Nat Immunol 2: 1061-1066
9. Fingerle-Rowson G, Petrenko O, Metz C, Forsthuber T, Mitchell R, Huss R, Moll U, Müller W, Bucala R (2003) The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting. Proc Natl Acad Sci USA 100: 9354-9359
10. Gaspar M, Arribas I, Coca M, Díez-Alonso M (2001) Prognostic value of carcinoembryonic antigen, CA 19-9 and CA 72-4 in gastric carcinoma. Tumour Biol 22: 318-322
11. Genta R (2004) Screening for gastric cancer: does it make sense? Aliment Pharmacol Ther 20: 42-47
12. He X, Yang J, Ding Y, Liu W, Shen Q, Xia H (2006) Increased epithelial and serum expression of macrophage migration inhibitory factor (MIF) in gastric cancer: potential role of MIF in gastric carcinogenesis. Gut 55: 797-802
13. Hudson J, Shoaibi M, Maestro R, Carnero A, Hannon G, Beach D (1999) A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med 190: 1375-1382
14. Ishigami S, Natsugoe S, Hokita S, Che X, Tokuda K, Nakajo A, Iwashige H, Tokushige M, Watanabe T, Takao S, Aikou T (2001) Clinical importance of preoperative carcinoembryonic antigen and carbohydrate antigen 19-9 levels in gastric cancer. J Clin Gastroenterol 32: 41-44
15. Japanese Gastric Cancer Association (1998) Japanese classification of gastric carcinoma. 1: 10-24
16. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun M (2007) Cancer statistics, 2007. CA Cancer J Clin 57: 43-66
17. Kobayashi T, Kikuchi S, Lin Y, Yagyu K, Obata Y, Ogihara A, Hasegawa A, Miki K, Kaneko E, Mizukoshi H, Sakiyama T, Tenjin H (2004) Trends in the incidence of gastric cancer in Japan and their associations with Helicobacter pylori infection and gastric mucosal atrophy. Gastric Cancer 7: 233-239
18. Koomen JM, Shih LN, Coombes KR, Li D, Xiao L-C, Fidler IJ, Abbruzzese JL, Kobayashi R (2005) Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin Cancer Res 11: 1110-1118
19. Krockenberger M, Dombrowski Y, Weidler C, Ossadnik M, Hönig A, Häusler S, Voigt H, Becker J, Leng L, Steinle A, Weller M, Bucala R, Dietl J, Wischhusen J (2008) Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D. J Immunol 180: 7338-7348
20. Lee H, Rhee H, Kang H, Kim H, Min B, Kim N, Kim H (2008) Macrophage migration inhibitory factor may be used as an early diagnostic marker in colorectal carcinomas. Am J Clin Pathol 129: 772-779
21. Lundy F, Orr D, Gallagher J, Maxwell P, Shaw C, Napier S, Gerald Cowan C, Lamey P, Marley J (2004) Identification and overexpression of human neutrophil alpha-defensins (human neutrophil peptides 1, 2 and 3) in squamous cell carcinomas of the human tongue. Oral Oncol 40: 139-144
22. Marrelli D, Pinto E, De Stefano A, Farnetani M, Garosi L, Roviello F (2001) Clinical utility of CEA, CA 19-9, and CA 72-4 in the follow-up of patients with resectable gastric cancer. Am J Surg 181: 16-19
23. Marrelli D, Roviello F, De Stefano A, Farnetani M, Garosi L, Messano A, Pinto E (1999) Prognostic significance of CEA, CA 19-9 and CA 72-4 preoperative serum levels in gastric carcinoma. Oncology 57: 55-62
24. Melle C, Ernst G, Schimmel B, Bleul A, Thieme H, Kaufmann R, Mothes H, Settmacher U, Claussen U, Halbhuber K, Von Eggeling F (2005) Discovery and identification of alpha-defensins as low abundant, tumor-derived serum markers in colorectal cancer. Gastroenterology 129: 66-73
25. Meyer-Siegler K, Bellino M, Tannenbaum M (2002) Macrophage migration inhibitory factor evaluation compared with prostate specific antigen as a biomarker in patients with prostate carcinoma. Cancer 94: 1449-1456
26. Miki K, Morita M, Sasajima M, Hoshina R, Kanda E, Urita Y (2003) Usefulness of gastric cancer screening using the serum pepsinogen test method. Am J Gastroenterol 98: 735-739
27. Müller C, Markovic-Lipkovski J, Klatt T, Gamper J, Schwarz G, Beck H, Deeg M, Kalbacher H, Widmann S, Wessels J, Becker V, Müller G, Flad T (2002) Human alpha-defensins HNPs-1, -2, and -3 in renal cell carcinoma: influences on tumor cell proliferation. Am J Pathol 160: 1311-1324
28. Murakami H, Akbar S, Matsui H, Onji M (2001) Macrophage migration inhibitory factor in the sera and at the colonic mucosa in patients with ulcerative colitis: clinical implications and pathogenic significance. Eur J Clin Invest 31: 337-343
29. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108
30. Rogers M, Clarke P, Noble J, Munro N, Paul A, Selby P, Banks R (2003) Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility. Cancer Res 63: 6971-6983
31. Shi X, Leng L, Wang T, Wang W, Du X, Li J, McDonald C, Chen Z, Murphy J, Lolis E, Noble P, Knudson W, Bucala R (2006) CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity 25: 595-606
32. Song J, Patel M, Rosenzweig C, Chan-Li Y, Sokoll L, Fung E, Choi-Miura N, Goggins M, Chan D, Zhang Z (2006) Quantification of fragments of human serum inter-alpha-trypsin inhibitor heavy chain 4 by surface-enhanced laser desorption/ionization-based immunoassay. Clin Chem 52: 1045-1053
33. Varis K, Sipponen P, Laxén F, Samloff I, Huttunen J, Taylor P, Heinonen O, Albanes D, Sande N, Virtamo J, Härkönen M (2000) Implications of serum pepsinogen I in early endoscopic diagnosis of gastric cancer and dysplasia. Helsinki Gastritis Study Group. Scand J Gastroenterol 35: 950-956
34. Villanueva J, Shaffer DR, Philip J, Chaparro C, Erdjument-Bromage H, Olshen AB, Fleisher M, Lilja H, Brogi E, Boyd J, Sanchez-Carbayo M, Holland EC, Cordon-Cardo C, Scher HI, Tempst P (2006) Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 116: 271-284
35. Ward DG, Nyangoma S, Joy H, Hamilton E, Wei W, Tselepis C, Steven N, Wakelam MJ, Johnson PJ, Ismail T, Martin A (2008) Proteomic profiling of urine for the detection of colon cancer Proteome Sci. 6: 19
36. Ward DG, Suggett N, Cheng Y, Wei W, Johnson H, Billingham LJ, Ismail T, Wakelam MJO, Johnson PJ, Martin A (2006) Identification of serum biomarkers for colon cancer by proteomic analysis. Br J Cancer 94: 1898-1905
37. Wilson J, Coletta P, Cuthbert R, Scott N, MacLennan K, Hawcroft G, Leng L, Lubetsky J, Jin K, Lolis E, Medina F, Brieva J, Poulsom R, Markham A, Bucala R, Hull M (2005) Macrophage migration inhibitory factor promotes intestinal tumorigenesis. Gastroenterology 129: 1485-1503
38. Xu X, Wang B, Ye C, Yao C, Lin Y, Huang X, Zhang Y, Wang S (2008) Overexpression of macrophage migration inhibitory factor induces angiogenesis in human breast cancer. Cancer Lett 261: 147-157